GlobeNewswire 2/4/2019 Global Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2026: Publication of New Phase II Eff...
GlobeNewswire 1/29/2019 Travelan® FY19 1st Half Update and Geographic Expansion into North America
GlobeNewswire 1/8/2019 Immuron Receives $1.19M R&D Tax Concession Refund
GlobeNewswire 11/9/2018 NASH clinical trial presentation and continued revenue growth
GlobeNewswire 9/17/2018 Global Microbiome Therapeutics & Diagnostics (Gastrointestinal, Metabolic, Cancer, Neurological, Aut...
GlobeNewswire 9/5/2018 US Department of Defense Reports Travelan Protects Against Shigella in Primates
GlobeNewswire 7/25/2018 Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year
GlobeNewswire 7/24/2018 Immuron Announces it has Received a European Patent Grant for NASH treatment
GlobeNewswire 7/24/2018 US Department of Defense Research Collaboration Moves Forward
GlobeNewswire 6/26/2018 Immuron Announces Board Appointment
GlobeNewswire 5/16/2018 Oral Proteins and Peptides Market, 2030
GlobeNewswire 5/8/2018 Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
GlobeNewswire 4/24/2018 Immuron CEO to Present at RedChip Global Online Growth Conference
GlobeNewswire 4/23/2018 Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets
GlobeNewswire 3/13/2018 Immuron Announces A$5.1M Private Placement to U.S. Fund
GlobeNewswire 3/13/2018 Immuron Progresses Discussions with Institutional Funds
GlobeNewswire 3/13/2018 UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow
GlobeNewswire 3/12/2018 Immuron Commences US Non-Deal Institutional Investor Roadshow
GlobeNewswire 3/8/2018 Immuron Reports Positive Results in NASH Clinical Trial
GlobeNewswire 3/7/2018 Immuron Limited Issues Correction to Misleading Halt Announcement Headline
GlobeNewswire 2/16/2018 Travelan® Revenue Grows Significantly in US and Australia
GlobeNewswire 1/31/2018 Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile In...
GlobeNewswire 1/29/2018 US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and ...
GlobeNewswire 1/24/2018 Immuron to Receive $2.16M R&D Tax Concession Refund
GlobeNewswire 1/10/2018 CEO to Present on US Investor TV Show and at Biotech Conference